drug · antibody
cemiplimab
Marketedupdated 5mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 15 sources
- drugLIBTAYO60 co-mentions · 15 sources
- tagOncology12 co-mentions · 3 sources
- tagPulmonology4 co-mentions · 1 sources
- tagNSCLC3 co-mentions · 1 sources
- tagBreast Cancer3 co-mentions · 1 sources
- tagMelanoma3 co-mentions · 1 sources
- tagColorectal Cancer2 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 25 investigational indications.
indications
investigational
NSCLCMelanoma
targets
Programmed cell death protein 1
all catalysts(17)
approval · 15
Sep 28, 2018
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jan 18, 2019
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 20, 2019
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jun 25, 2020
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 10, 2020
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 22, 2021
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 8, 2022
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 28, 2023
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 28, 2023
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 6, 2024
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 5, 2024
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Oct 8, 2025
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Oct 29, 2025
approval
$REGN746.54+0.94%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
phase 1 completion · 1
Trials studying cemiplimab
- phase3A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- phase2A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- phase2Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
- phase2Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- phase2REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
- phase3A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- phase3Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- phase2RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
News(5)
- Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancerHighlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell carcinoma (BCC).fiercebiotech · 11d ago
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 27d ago
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 2mo ago
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…biopharma_dive · 4mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 5mo ago
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that